TLR9 and neoplasm: In addition, many clinical trials (phase I-III) evaluate the activation of pDCs in the tumor using TLR7 and TLR9 agonists—which reactivate their production of type I IFN and cytotoxic molecules (e.g., TRAIL) [66].